+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
FEMALE
ID06167694

Study of HRS-8080 and Dalpiciclib Isethionate Tablets for Women with Advanced ER-positive, HER2-negative Breast Cancer Phase IbII Open-Label Trial Evaluating Safety and Effectiveness

Led by Shandong Suncadia Medicine Co., Ltd. · Updated on 2026-01-09

146

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a multicenter, open-label phase IbII clinical study to evaluate the safety, tolerability, and effectiveness of the combination of HRS-8080 and Dalpiciclib Isethionate Tablets in women with estrogen receptor-positive, HER2-negative unresectable or metastatic breast cancer. This study is divided into two phases a dose exploration phase and an efficacy expansion phase, aiming to find the best dose and assess the response to treatment in this patient population. Participants will receive treatment combining HRS-8080 with Dalpiciclib Isethionate Tablets. The study includes a dose exploration period to determine the maximum tolerated dose and recommended dose for phase II, followed by an expansion phase to evaluate treatment efficacy. Treatments are given according to the study protocol, and the entire study period is expected to last about two years. During the study, participants will be closely monitored for safety through assessments of adverse events and serious adverse events. Researchers will measure key outcomes such as dose-limiting toxicities, objective response rate, and other response-related measures including duration and progression-free survival. Participants will undergo various evaluations including physical status assessments, imaging to confirm measurable lesions, and laboratory tests. The study requires participants to follow study visits and procedures consistently throughout the treatment and observation period.

CONDITIONS

Brief Title

Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

Research Team

M

Min Li

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here